Visseren, Frank L.J.

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 8,961

2021 ESC Guidelines on cardiovascular disease prevention in clinical practice

Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2021) · European Heart Journal

Health Promotion and Cardiovascular PreventionClinical practice guidelines implementation

Cited by 6,485

2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 4,854

2024 ESC Guidelines for the management of elevated blood pressure and hypertension

McEvoy, J. W., McCarthy, C. P., Bruno, R. M., Brouwers, S., Canavan, M. D., Ceconi, C., Christodorescu, R. M., Daskalopoulou, S. S., Ferro, C. J., Gerdts, E., et al. (2024) · European Heart Journal

Blood Pressure and Hypertension StudiesClinical practice guidelines implementation

Cited by 2,298

SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe

SCORE2 working group and ESC Cardiovascular risk collaboration, Hageman, S., Pennells, L., Ojeda, F., Kaptoge, S., Kuulasmaa, K., de Vries, T., Xu, Z., Kee, F., Chung, R., et al. (2021) · European Heart Journal

Health Promotion and Cardiovascular PreventionCardiovascular Health and Risk Factors

Cited by 1,810

2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.

Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 1,642

Adipose tissue dysfunction in obesity, diabetes, and vascular diseases

Hajer, G. R., van Haeften, T. W., & Visseren, F. L. J. (2008) · European Heart Journal

Adipokines, Inflammation, and Metabolic DiseasesCardiovascular Disease and Adiposity

Cited by 1,410

Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia

Kastelein, J. J. P., Akdim, F., Stroes, E. S. G., Zwinderman, A. H., Bots, M. L., Stalenhoef, A. F. H., Visseren, F. L. J., Sijbrands, E. J. G., Trip, M. D., Stein, E. A., et al. (2008) · New England Journal of Medicine

Lipoproteins and Cardiovascular HealthCardiovascular Health and Disease Prevention

Cited by 1,241

Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol

Ray, K. K., Landmesser, U., Leiter, L. A., Kallend, D., Dufour, R., Karakas, M., Hall, T., Troquay, R. P. T., Turner, T., Visseren, F. L. J., et al. (2017) · New England Journal of Medicine

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 992

Obesity and cancer: the role of dysfunctional adipose tissue

van Kruijsdijk, R. C. M., van der Wall, E., & Visseren, F. L. J. (2009) · Cancer Epidemiology, Biomarkers & Prevention

Adipokines, Inflammation, and Metabolic DiseasesCancer Risks and Factors

Cited by 715

SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe

SCORE2-Diabetes Working Group and the ESC Cardiovascular Risk Collaboration, Pennells, L., Kaptoge, S., Østergaard, H. B., Read, S. H., Carinci, F., Franch-Nadal, J., Petitjean, C., Taylor, O., Hageman, S. H. J., et al. (2023) · European Heart Journal

Diabetes, Cardiovascular Risks, and LipoproteinsHealth Promotion and Cardiovascular Prevention

Cited by 329

Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial

Ray, K. K., Troquay, R. P. T., Visseren, F. L. J., Leiter, L. A., Scott Wright, R., Vikarunnessa, S., Talloczy, Z., Zang, X., Maheux, P., Lesogor, A., et al. (2023) · The Lancet Diabetes & Endocrinology

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 328

Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Gouni-Berthold, I., Alexander, V. J., Yang, Q., Hurh, E., Steinhagen-Thiessen, E., Moriarty, P. M., Hughes, S. G., Gaudet, D., Hegele, R. A., O'Dea, L. S. L., et al. (2021) · The Lancet Diabetes & Endocrinology

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 232

Prevalence of the metabolic syndrome in patients with coronary heart disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm

Gorter, P. M., Olijhoek, J. K., van der Graaf, Y., Algra, A., Rabelink, T. J., & Visseren, F. L. J. (2004) · Atherosclerosis

Diabetes, Cardiovascular Risks, and LipoproteinsCardiovascular Health and Risk Factors

Cited by 216

Continuous glucose monitoring in adults with type 2 diabetes: a systematic review and meta-analysis

Jancev, M., Vissers, T. A. C. M., Visseren, F. L. J., van Bon, A. C., Serné, E. H., DeVries, J. H., de Valk, H. W., & van Sloten, T. T. (2024) · Diabetologia

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 191

Estimating treatment effects for individual patients based on the results of randomised clinical trials

Dorresteijn, J. A. N., Visseren, F. L. J., Ridker, P. M., Wassink, A. M. J., Paynter, N. P., Steyerberg, E. W., van der Graaf, Y., & Cook, N. R. (2011) · BMJ

Lipoproteins and Cardiovascular HealthStatistical Methods in Clinical Trials

Cited by 177

Prediction of individualized lifetime benefit from cholesterol lowering, blood pressure lowering, antithrombotic therapy, and smoking cessation in apparently healthy people

Jaspers, N. E. M., Blaha, M. J., Matsushita, K., van der Schouw, Y. T., Wareham, N. J., Khaw, K.-T., Geisel, M. H., Lehmann, N., Erbel, R., Jöckel, K.-H., et al. (2020) · European Heart Journal

Health Promotion and Cardiovascular PreventionLipoproteins and Cardiovascular Health

Cited by 120

Familial dysbetalipoproteinemia: An underdiagnosed lipid disorder

Koopal, C., Marais, A. D., & Visseren, F. L. J. (2017) · Current Opinion in Endocrinology, Diabetes & Obesity

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 101

Inflammatory characteristics of distinct abdominal adipose tissue depots relate differently to metabolic risk factors for cardiovascular disease

Kranendonk, M. E. G., van Herwaarden, J. A., Stupkova, T., Jager, W. D., Vink, A., Moll, F. L., Kalkhoven, E., & Visseren, F. L. J. (2015) · Atherosclerosis

Adipokines, Inflammation, and Metabolic DiseasesCardiovascular Disease and Adiposity

Cited by 91

Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week multicenter, randomized, double-blind, controlled trial

Huijgen, R., Abbink, E. J., Bruckert, E., Stalenhoef, A. F. H., Imholz, B. P. M., Durrington, P. N., Trip, M. D., Eriksson, M., Visseren, F. L. J., Schaefer, J. R., et al. (2010) · Clinical Therapeutics

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 80

Iron chelation and hydroxyl radical scavenging reduce the inflammatory response of endothelial cells after infection with Chlamydia pneumoniae or influenza A

Visseren, F. L. J., Verkerk, M. S. A., Van Der Bruggen, T., Marx, J. J. M., Van Asbeck, B. S., & Diepersloot, R. J. A. (2002) · European Journal of Clinical Investigation

Nitric Oxide and Endothelin EffectsNeutrophil, Myeloperoxidase and Oxidative Mechanisms

Cited by 64

Vascular risk factors, vascular disease, lipids and lipid targets in patients with familial dysbetalipoproteinemia: A European cross-sectional study

Koopal, C., Retterstøl, K., Sjouke, B., Hovingh, G. K., Ros, E., de Graaf, J., Dullaart, R. P. F., Bertolini, S., & Visseren, F. L. J. (2015) · Atherosclerosis

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 58

Addressing residual risk beyond statin therapy: New targets in the management of dyslipidaemias–A report from the European Society of Cardiology Cardiovascular Round Table

Mach, F., Visseren, F. L. J., Cater, N. B., Salhi, N., Soronen, J., Ray, K. K., Delgado, V., Jukema, J. W., Laufs, U., Zamorano, J.-L., et al. (2024) · Journal of Clinical Lipidology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 57

Autosomal dominant familial dysbetalipoproteinemia: A pathophysiological framework and practical approach to diagnosis and therapy

Koopal, C., Marais, A. D., Westerink, J., & Visseren, F. L. J. (2017) · Journal of Clinical Lipidology

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 53